以多西他赛为主二联与三联疗法对老年低分化胃癌的疗效对比分析

目的对比以多西他赛为主二联和三联疗法对老年低分化胃癌的临床效果。方法将60例老年低分化胃癌患者随机分成三联化疗组和二联化疗组,每组30例。二联化疗组给予多西他赛联合奥沙利铂方案化疗,三联化疗组给予多西他赛联合奥沙利铂、替吉奥方案化疗。对两组近期疗效、KPS评分、肿瘤进展时间(TTP)、生存时间(OS)及不良反应进行比较。结果二联化疗组客观缓解率、临床获益率为36.7%、63.3%,三联化疗组客观缓解率、临床获益率为33.3%、70.0%,差异无统计学意义(P0.05);治疗后,二联化疗组KPS评分为(71.5±6.6)分,显著性低于三联化疗组的(79.5±7.9)分,差异有统计学意义(P0.05);二联化疗组TTP为8.5个月,三联化疗组TTP为8.7个月,差异无统计学意义(P0.05);二联化疗组OS为13.4个月,三联化疗组OS为15.1个月,差异无统计学意义(P0.05);二联化疗组不良反应(白细胞降低、贫血、乏力)率显著低于三联化疗组,差异有统计学意义(P0.05)。结论相比于多西他赛为主三联疗法,多西他赛为主二联疗法对对老年低分化胃癌效果同样显著,且不良反应较少,适合老年人使用。

Comparison of clinical effect between docetaxel-containing double regimen and triple regimen for elder-ly patients with unresectable gastric cancer

Objective To compare the clinical efficacy of docetaxel-containing double regimen and triple regimen for elderly patients with unresectable advanced gastric cancer. Methods Sixty elderly patients with unresectable advanced poorly differentiated gastric cancer were randomly divided into double regimen group and triple regimen group, 30 cases in each group. Patients in double regimen group were treated by doc-etaxel combined with oxaliplatin, and patients in triple regimen group were treated by docetaxel combined with oxaliplatin and S-1. The short-term efficacy, KPS score, time to tumor progression （TTP）, overall survival time （OS）, and adverse reactions were compared. Results The objective response rate and clinical benefit rate were 36.7%and 63.3%in double regimen group , and 33.3%and 70.0%in triple regimen group （P〉0.05）;After treatment, the KPS score in double regimen group was 71.5 ± 6.6, which was significantly lower than 79.5 ± 7.9 points in triple regimen group （P〈0.05）; The TTPs of double regimen group and triple regimen group were 8.5 months and 8.7 months, the difference was not statistically significant （P〉0.05）; The OS of double regimen group and triple regimen group were 13.4 months and 15.1 months, the difference was not sta-tistically significant （P〉0.05）. The rate of adverse reaction （leukopenia, anemia, fatigue） in double regimen group was significantly lower than in triple regimen group （P〈0.05）. Conclusion Compared with docetaxel-based triple therapy, docetaxel-based double therapy also has good effect for elderly patients with unresectable poorly differentiated gastric cancer.